Related Experiment Video
Updated: Jul 3, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis
Leona Yip1, Shannon Harrison, Peter Foley
1Department of Dermatology, St Vincent's Hospital Melbourne, and The University of Melbourne, Fitzroy, Victoria, Australia. leonaywy@yahoo.co.nz
Abstract:
Differences in mode of action between biologic agents could explain why one agent is more efficacious than another in the treatment of recalcitrant and erythrodermic flares of chronic plaque psoriasis. Here, we present our experience using a case series of three patients with chronic plaque psoriasis who showed consistent and similar responses to three different biologic agents. All three patients who were refractory to efalizumab developed erythrodermic flares 2-12 weeks after a direct switch to etanercept. Switching from efalizumab to etanercept could provoke paradoxical flaring of psoriasis, which might be prevented by transitioning to systemic agents. The erythrodermic flares in all three patients responded dramatically to infliximab with marked and maintained improvements in Psoriasis Area and Severity Index scores.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Crohn's Disease
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...